The Trans-Pacific Partnership and Its Effect On Biosimilars [Inside Counsel]

Aaron Lukas and Keri Schaubert, associates of Cozen O’Connor’s IP group, discuss the effect that the Trans-Pacific Partnership will have on the biopharmaceutical and biosimilar industry. The Trans-Pacific Partnership is expected to face a tough battle in Congress, with exclusivity for biologic drugs a key concern for making of the law makers.  Once the TTP is passed, American biopharmaceutical companies will have greater protection in the overseas markets and patients will benefit from the introduction of biosimilar products whose exclusivity has expired. 

To read more click here.

Share Page On LinkedIn

Related Attorneys

Aaron Lukas, Ph.D.

Co-Chair, Hatch-Waxman & Biologics

(202) 912-4823

Keri L. Schaubert, Ph.D.


(212) 883-2258

Related Practices